Med Fusion Selects N-of-One
Complete the form below to unlock access to ALL audio articles.
N-of-One Inc has announced that med fusion has selected N-of-One to provide integrated interpretation of med fusion’s new HemeSEQ™ profiles for AML, CLL, DLBCL and MPN diseases. MDS and Myeloid profiles are in development and will be made available later this year. Financial terms of the agreement are not disclosed. med fusion’s HemeSEQ profiles help physicians rapidly diagnose, predict the course of disease progression and identify relevant clinical trial and treatment options for patients living with hematologic diseases.
The HemeSEQ profiles expand med fusion’s hematological menu to nearly 100 tests by incorporating next generation sequencing (NGS) technology to provide physicians with an understanding of the molecular basis of the disease – an important component emphasized by the latest World Health Organization (WHO) recommendations to improve care of patients with hematologic neoplasms – without extending turnaround time or increasing specimen requirements.
The cumulative findings are delivered via an integrated report that includes cytogenetic abnormalities and molecular mutations identified and matched to relevant clinical trial and therapy options for each patient utilizing N-of-One’s case analysis and proprietary knowledgebase and med fusion’s genetic analysts. The HemeSEQ profiles can be ordered as standalone profiles by the treating physician and are also part of med fusion’s Comprehensive Heme (HEMC) Testing Service.
HEMC assessments include information from flow cytometry, morphology, chromosomal analysis, FISH and molecular testing. A final diagnosis is provided in a comprehensive report detailing the results of all services performed by med fusion including therapeutic and clinical trial options for the patient based upon the biology of their disease.
“Partnering with N-of-One enables us to scale to address our growing volume of molecular diagnostic tests for patients living with hematologic neoplasms,” said Jon Hart, CEO of med fusion. “Our vision is to provide responsible precision medicine solutions that enable best-in-class patient care. We selected N-of-One because we believe the quality of their work will help support this vision by providing the very best diagnostic, clinical trial and treatment options to our oncologist clients.”
“The N-of-One team is very pleased to partner with med fusion because we share their mission to deliver the highest quality molecular diagnostic services with fast turnaround time for their cancer patients. med fusion is a leading molecular diagnostic lab, and we are delighted to help them to grow their business,” said Chris Cournoyer, CEO at N-of-One.
Source: Story from Med Fusion. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
